Information Provided By: 
Fly News Breaks for November 16, 2015
AZN, CLVS
Nov 16, 2015 | 10:27 EDT
Goldman Sachs analyst Terence Flynn put his Conviction Buy rating and $123 price target on Clovis Oncology (CLVS) under review following this morning's regulatory update for rociletinib. The news is a "significant setback," especially since the updated response rates are below that of AstraZeneca's (AZN) competitor drug, Flynn tells investors in a research note.
News For CLVS;AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
AZN
Apr 25, 2024 | 05:49 EDT
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
